Condition: Chronic Kidney Disease Requiring Chronic Dialysis · Sponsor: Unicycive Therapeutics, Inc
The goal of this clinical study is to test the tolerability of oxylanthanum carbonate (OLC) in patients with chronic kidney disease on hemodialysis and have hyperphosphatemia (too much phosphorus in their blood). The main question it aims to answer is whether patients taking OLC for hyperphosphatemia are able to tolerate the drug. Participants will continue with their scheduled dialysis treatments and replace their current phosphate binder drug with OLC.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| US Renal Care | Pine Bluff, Arkansas, United States | — |
| US Renal Care | Fort Myers, Florida, United States | — |
| US Renal Care | Gallup, New Mexico, United States | — |
| US Renal Care | Cheektowaga, New York, United States | — |
| US Renal Care | Toledo, Ohio, United States | — |
| US Renal Care | San Antonio, Texas, United States | — |
| Clinical Advancement Center, PLLC | San Antonio, Texas, United States | — |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06218290